Medtronic to assess "low glucose suspend" technology

10/30/2011 | Pioneer Press (St. Paul, Minn.)

Medtronic announced last week that it has received government approval to evaluate an experimental feature of its insulin pumps called low glucose suspend technology, which stops insulin delivery for two hours when a patient's blood glucose level gets too low. Experts said the technology is an important step toward the development of an artificial pancreas system.

View Full Article in:

Pioneer Press (St. Paul, Minn.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN